NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
JUBLCPL FY26 PAT Surges 46% to ₹1,279 MN; Agri Segment Revenue Grows 52%
JUBLCPL reported a strong performance for FY26, with consolidated revenue growing 21% to ₹18,911 million and PAT increasing 46% to ₹1,279 million. The Agri Products segment was a major growth driver, with revenue jumping 52% to ₹6,923 million, while the Adhesives business maintained steady double-digit growth. The company maintains a healthy balance sheet with a very low debt-to-equity ratio of 0.06x and a high ROCE of 37%. A key upcoming catalyst is the commencement of a new adhesive manufacturing facility in Q1 FY27 and the ongoing demerger of the Agri business.
முக்கிய அம்சங்கள்
Consolidated FY26 Revenue grew 21% YoY to ₹18,911 million, while EBITDA rose 34% to ₹1,960 million.Agri Products segment revenue surged 52% to ₹6,923 million in FY26, driven by better placement of SSP fertilizers.Adhesives business sustained momentum with 16% revenue growth and 20% EBIT growth for the full year.Balance sheet remains robust with Net Debt to Equity at 0.06x and ROCE improving to 37%.New adhesive manufacturing facility at Samlya, Gujarat, is scheduled to commence operations in Q1 FY27.
👀 கவனிக்க வேண்டியவை
Investors should view the strong earnings growth and low leverage positively, while monitoring the progress of the Agri division demerger. The upcoming capacity expansion in the high-margin adhesive segment provides a visible growth runway.
Jubilant Agri and Consumer Products FY26 Net Profit Jumps 43.8% to ₹127.6 Crore
Jubilant Agri and Consumer Products Limited (JUBLCPL) delivered a robust performance for the financial year ended March 31, 2026, with standalone revenue growing 20.5% YoY to ₹1,857.2 crore. Net profit for the full year surged by 43.8% to ₹127.6 crore, driven by strong growth in the P&K Fertilizers segment. The company's EPS improved significantly from ₹58.88 to ₹84.49. Additionally, the company is progressing with a strategic demerger of its Agri Division into a separate entity, Jubilant Agri Solutions Limited.
முக்கிய அம்சங்கள்
Annual Standalone Revenue increased by 20.5% YoY to ₹1,85,718 lakhs in FY26.Full-year Net Profit grew by 43.8% to ₹12,763 lakhs compared to ₹8,873 lakhs in FY25.P&K Fertilizers segment revenue surged 54.3% YoY to ₹68,119 lakhs.Performance Polymers & Chemicals segment revenue grew to ₹1,20,467 lakhs from ₹1,10,779 lakhs.The Board is proceeding with a 1:1 demerger scheme for the Agri Division to unlock value.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong margin expansion and the high growth in the fertilizer segment. The upcoming demerger of the Agri Division is a key catalyst to watch for potential value unlocking.
Jubilant Ingrevia Q4 FY26 PAT Rises 17% YoY to ₹86 Cr; Total Dividend at ₹5 per Share
Jubilant Ingrevia reported a strong Q4 FY26 with revenue growing 12% YoY to ₹1,179 crore, marking its highest revenue in 14 quarters. Profit After Tax (PAT) increased 17% YoY to ₹86 crore, supported by a 10% volume growth and effective cost pass-through despite global supply chain disruptions. The Specialty Chemicals segment maintained robust margins of 27%, while the Nutrition business saw a 21% revenue jump. The company also improved its balance sheet, reducing net debt by 11% and achieving a healthy Net Debt/EBITDA ratio of 0.99x.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue reached ₹1,179 crore, a 12% YoY increase driven by 10% volume growth.EBITDA for the quarter stood at ₹172 crore, up 11% YoY and 26% sequentially (QoQ).Board recommended a final dividend of ₹2.50 per share, bringing the total FY26 dividend to ₹5 per share (500%).Specialty Chemicals segment EBITDA grew 21% in FY26, now contributing 75% to the total company EBITDA.Net Debt decreased by 11% in FY26, resulting in a significantly improved Net Debt/EBITDA ratio of 0.99x.
👀 கவனிக்க வேண்டியவை
Investors should note the strong volume recovery and margin stability in the Specialty Chemicals and CDMO segments as evidence of the 'Pinnacle' strategy's success. The reduction in debt and consistent dividend payout make it a compelling watch for long-term growth in the specialty chemicals space.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia Limited has announced a final dividend of Rs 2.50 per equity share, representing a 250% payout on its Re 1 face value for the financial year ended March 31, 2026. The company has established July 24, 2026, as the record date for determining eligibility, with the payout expected within 30 days of the AGM. Alongside the dividend, the board confirmed the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This move signals a stable financial outlook and a consistent shareholder reward policy.
முக்கிய அம்சங்கள்
Recommended a final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face valueFixed Friday, July 24, 2026, as the record date for the purpose of final dividend paymentRe-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27The dividend payout is subject to shareholder approval at the upcoming Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the shares before the record date of July 24, 2026. The 250% dividend payout indicates a healthy cash flow position and management's commitment to returning value to shareholders.
Jubilant Pharmova Subsidiary Receives Rs 107.89 Cr Income Tax Adjustment Order
Jubilant Pharmova's step-down subsidiary, Jubilant Generics Limited (JGL), has received a tax order for FY 2022-23 involving adjustments of Rs 107.89 crores. The adjustments primarily stem from transfer pricing issues, which the company claims ignore its previous contentions. While the company is filing an appeal and expects relief, it has already identified a reduction in Deferred Tax Assets by Rs 37.70 crores. Management does not anticipate any other material financial implications following the redressal process.
முக்கிய அம்சங்கள்
Income Tax Department issued an order for FY 23 making tax adjustments of Rs 107.89 crores.Adjustments are primarily related to transfer pricing disputes within the subsidiary Jubilant Generics Limited.The company has reported a reduction in Deferred Tax Assets (DTA) amounting to Rs 37.70 crores.JGL is in the process of filing an appeal before the Commissioner of Income Tax (Appeals) and the Advance Pricing Authority.Management expects the impugned tax adjustments to be deleted post-adjudication.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the appeal process as tax disputes can be prolonged, though the immediate cash flow impact appears limited. The Rs 37.70 crore reduction in Deferred Tax Assets is a notable accounting impact to consider in the near term.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Jubilant Pharmova Appoints Ashish Mukkirwar as CFO and Priyavrat Bhartia as MD
Jubilant Pharmova is undergoing a significant leadership transition with the appointment of Mr. Ashish Mukkirwar as CFO (effective May 23, 2026) and Mr. Priyavrat Bhartia as Managing Director (effective June 1, 2026). Mr. Mukkirwar, an IIM Kolkata alumnus, joins from Glenmark Pharmaceuticals where he served as Group VP & CFO for Global Formulations. The outgoing CFO, Mr. Arun Kumar Sharma, will transition into an advisory role for the Chairmen after relinquishing his post on May 22, 2026. These appointments bring seasoned pharmaceutical industry expertise to the company's top management.
முக்கிய அம்சங்கள்
Mr. Ashish Mukkirwar appointed as CFO and KMP effective May 23, 2026, bringing over 20 years of experience.Mr. Priyavrat Bhartia to take charge as Managing Director of the company starting June 1, 2026.Outgoing CFO Mr. Arun Kumar Sharma moves to a new role as Advisor to the Chairmen.New CFO has a strong pedigree, previously holding senior roles at Glenmark Pharmaceuticals, Moelis & Company, and UBS Investment Banking.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic move to strengthen leadership with experienced professionals from the pharma sector. Monitor for any changes in capital allocation or M&A strategy under the new leadership team.
Jubilant Pharmova reported a solid 14% YoY revenue growth for FY26, reaching Rs 8,280 crore, led by a 38% surge in the CDMO Sterile Injectables segment. Annual EBITDA grew 8% to Rs 1,326 crore, although Q4 margins faced pressure due to a temporary shutdown at the Montreal facility for FDA remediation. The company has successfully onboarded a major oncology product at its Spokane facility and proposed a dividend of Rs 5 per share. Management anticipates margin strengthening from H2'FY27 as production at Montreal stabilizes.
முக்கிய அம்சங்கள்
FY26 Revenue increased 14% YoY to Rs 8,280 Cr, with Normalised PAT growing 7% to Rs 442 Cr.CDMO Sterile Injectables revenue grew 38% to Rs 1,755 Cr, driven by the ramp-up of Line 3 at the Spokane facility.Ruby-Fill install base in the Radiopharma segment grew by 35% in FY26 compared to 21% in FY25.The Board proposed a dividend of Rs 5 per equity share for the financial year ended March 31, 2026.Net Debt to EBITDA ratio remained stable at 1.3x as of March 2026 despite ongoing growth investments.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful onboarding of the large oncology product and the expected margin recovery in H2'FY27. The integration of API and Drug Discovery into Jubilant Biosys is a positive move for long-term operational efficiency.
Jubilant Pharmova Re-appoints MD and Joint MD for 3-Year Terms Effective June 2026
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director. Both appointments are for a three-year duration starting June 1, 2026, pending shareholder approval. The leaders have been part of the board since 2017 and in their current executive roles since June 2023. This move ensures continuity in the company's strategic management and long-term vision.
முக்கிய அம்சங்கள்
Re-appointment of Priyavrat Bhartia as MD for a 3-year term effective June 1, 2026.Re-appointment of Arjun Shanker Bhartia as Joint MD for a 3-year term effective June 1, 2026.Priyavrat Bhartia brings 29 years of industry experience with an MBA from Stanford University.Arjun Shanker Bhartia is a Brown University graduate with prior strategy experience at Bain & Company.
👀 கவனிக்க வேண்டியவை
Investors should view this as a sign of management stability and continuity in strategic direction. No immediate action is required as these are expected re-appointments of the promoter-led management team.
Jubilant Pharmova Recommends 500% Dividend of Rs 5 Per Share; Sets July 24 as Record Date
Jubilant Pharmova's Board has recommended a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, representing a 500% payout on its Re 1 face value. The company has officially fixed July 24, 2026, as the record date to determine shareholder eligibility for this payment. This announcement accompanied the release of the company's audited financial results, which received an unmodified opinion from statutory auditors Walker Chandiok & Co LLP. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
முக்கிய அம்சங்கள்
Recommended a final dividend of 500% amounting to Rs 5 per equity share of face value Re 1.Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment.Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.Statutory auditors issued an unmodified opinion, confirming the accuracy of the financial statements.Dividend payment will be processed within 30 days from the date of the Annual General Meeting.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the shares before the July 24 record date to be eligible for the Rs 5 per share payout. The clean audit report further reinforces confidence in the company's reported financial performance.
Jubilant Foodworks Q4 FY26: Consolidated Revenue Up 19.3% YoY, PAT Surges 67.3%
Jubilant Foodworks reported a robust consolidated performance for Q4 FY26, with revenue reaching ₹24,995 million, a 19.3% YoY increase. Consolidated PAT from continued operations jumped 67.3% YoY to ₹936 million, supported by a 69 bps expansion in EBITDA margins to 19.4%. While India standalone revenue grew 6.4% with a modest 0.2% LFL growth for Domino's, the company saw a strong 10.4% YoY growth in orders. The global store network expanded to 3,636 stores, with 351 net additions during FY26.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q4 FY26 grew 19.3% YoY to ₹24,995 mn; FY26 Revenue stood at ₹95,125 mn.Consolidated PAT from continued operations surged 67.3% YoY to ₹936 mn in Q4 FY26.Domino's India recorded 10.4% YoY order growth, though LFL growth was muted at 0.2% for the quarter.Popeyes India demonstrated strong momentum with 28% SSG in FY26, reaching a total of 78 stores.Free Cashflow to Firm (FCFF) for the consolidated entity improved to ₹2,472 mn in FY26 from ₹2,422 mn in FY25.
👀 கவனிக்க வேண்டியவை
Investors should note the strong consolidated growth and margin improvement despite soft LFL growth in the domestic Domino's business. The rapid scaling of Popeyes and strong performance in international markets like Turkey provide significant growth diversification.
Jubilant Foodworks Recommends Rs 1.2 Dividend per Share for FY26
Jubilant Foodworks' Board has recommended a dividend of Rs 1.2 per equity share for the financial year ended March 31, 2026. This represents a 60% payout on the face value of Rs 2 per share. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also approved its audited standalone and consolidated financial results for the year with an unmodified audit opinion.
முக்கிய அம்சங்கள்
Recommended dividend of INR 1.2 per equity share for FY 2025-26Dividend payout ratio stands at 60% of the face value of INR 2 per shareAudited financial results for the year ended March 31, 2026, approved with an unmodified opinionDividend to be paid within 30 days of approval at the Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming AGM date for the record date and dividend payment timeline. The unmodified audit report confirms the reliability of the financial statements.
United Breweries to Close Ludhiana Unit by June 2026; Secures Contract Brewing Lease
United Breweries Limited (UBL) has announced the closure of its brewery unit in Ludhiana, Punjab, effective June 30, 2026. To ensure supply continuity in Punjab, Delhi, and neighboring states, the company has entered into a long-term capacity lease agreement with a Contract Brewing Unit. Management expects this move to enhance operational efficiency and sustainability without impacting business performance in the region. The company has reaffirmed its commitment to supporting affected employees during this transition period.
முக்கிய அம்சங்கள்
Closure of Ludhiana Brewery unit scheduled for June 30, 2026Long-term capacity lease agreement signed with a Contract Brewing Unit to secure supplySupply chain maintained for Punjab, Delhi, and neighboring statesManagement confirms no expected impact on business performance in the StateStrategic shift aimed at meeting future demand through enhanced operational efficiency
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic operational restructuring that mitigates risk through contract brewing. Monitor for any potential one-time closure costs or improvements in regional margins in future earnings reports.
UBL Wins Tax Litigation; ₹275 Crore Demand Reduced to Nil by Maharashtra Sales Tax Tribunal
United Breweries Limited (UBL) has successfully resolved a significant tax dispute dating back to FY 2018-2019. The Maharashtra Sales Tax Tribunal has passed a favorable order, reducing a Central Sales Tax demand that was originally ₹275 Crores to Nil. This follows a previous reduction to ₹7 Crores by the First Appellate Authority in 2024. The final ruling eliminates a major contingent liability, providing clarity and financial relief to the company's balance sheet.
முக்கிய அம்சங்கள்
Maharashtra Sales Tax Tribunal rules in favor of UBL, reducing tax demand to NilOriginal demand of ₹275 Crores for FY 2018-2019 was issued in March 2023Demand was previously reduced to ₹7 Crores in March 2024 before this final resolutionThe ruling results in a complete reduction of the associated contingent liability
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that removes a significant legal and financial overhang. The resolution of this ₹275 Crore dispute strengthens the company's risk profile and financial position.
UBL Reports Inadvertent Leak of Draft Annual Financial Results to External Individual
United Breweries Limited (UBL) has informed stock exchanges of a breach involving Unpublished Price Sensitive Information (UPSI) on May 5, 2026. An employee inadvertently shared draft annual financial results with one outside individual without following prescribed security protocols. The company stated that the official results were released to the public within a few hours of this leak, which may have limited the potential for unfair trading. UBL is treating this as a governance disclosure and plans to take legal action against the responsible party in accordance with SEBI regulations.
முக்கிய அம்சங்கள்
Inadvertent disclosure of draft annual financial results occurred on May 5, 2026UPSI was shared with one outside individual without necessary safeguardsOfficial financial results were disclosed to exchanges within a few hours of the leakCompany is initiating necessary legal action under SEBI (Prohibition of Insider Trading) RegulationsDisclosure made as a matter of good corporate governance and compliance
👀 கவனிக்க வேண்டியவை
Investors should monitor for any further regulatory action from SEBI regarding internal control lapses. While the immediate impact is low due to the quick official disclosure, it raises minor concerns regarding the company's data handling protocols.
United Breweries Submits Q4FY2026 Investor Presentation; Earnings Call Set for May 06
United Breweries Limited (UBL) has filed its investor presentation for the fourth quarter and the full financial year ended March 31, 2026. This disclosure follows the announcement of the company's audited financial results and serves as a precursor to the earnings call scheduled for May 06, 2026. The presentation provides a detailed breakdown of the company's operational and financial performance for FY26. Investors use these presentations to gauge volume trends and the success of premiumization strategies in the beer industry.
முக்கிய அம்சங்கள்
UBL released the investor presentation for the quarter and full year ended March 31, 2026.A formal earnings call is scheduled for May 06, 2026, to discuss the audited financial results.The filing is a mandatory disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.The presentation covers the company's strategic and financial performance for the entire 2025-26 fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should review the presentation for specific data on volume growth and margin expansion before the earnings call on May 06. Pay close attention to management commentary regarding raw material pricing and regional demand trends.
United Breweries Sets August 07, 2026, as Record Date for Dividend Eligibility
United Breweries Limited (UBL) has fixed August 07, 2026, as the record date to determine shareholder eligibility for dividend payments for the financial year. This decision follows the Board meeting held on May 05, 2026, where the 27th Annual General Meeting (AGM) was also scheduled for August 12, 2026. The final dividend payout remains subject to shareholder approval at the upcoming AGM. Investors must hold the stock before the record date to be eligible for the corporate action.
முக்கிய அம்சங்கள்
Record date for dividend eligibility is fixed as Friday, August 07, 2026The 27th Annual General Meeting (AGM) is scheduled for Wednesday, August 12, 2026Board meeting on May 05, 2026, lasted approximately 6.5 hours (12:15 PM to 6:45 PM)Dividend payment is contingent upon approval by members at the ensuing AGM
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they own the shares before the ex-dividend date (typically one day before the record date). Monitor the AGM results on August 12 for final confirmation of the dividend payout.
United Breweries Recommends ₹10 Dividend; FY26 Net Profit Dips to ₹413 Crore
United Breweries Limited (UBL) has recommended a final dividend of ₹10 per share for FY26, subject to shareholder approval. For the full year, the company reported a total income of ₹17,500 crore, down from ₹19,436 crore in FY25. Annual net profit decreased by 6.3% to ₹413.16 crore, although Q4 FY26 profit showed a slight year-on-year improvement to ₹101.67 crore. The company continues to contest a ₹751.83 crore CCI penalty, which remains a significant contingent liability.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share of face value ₹1 each.Full-year FY26 revenue from operations (gross) stood at ₹17,456 crore, a 10% decline compared to FY25.Annual Net Profit for FY26 decreased to ₹413.16 crore from ₹441.17 crore in the previous year.Q4 FY26 Net Profit rose slightly to ₹101.67 crore from ₹97.38 crore in Q4 FY25.Contingent liability of ₹751.83 crore persists regarding the CCI penalty currently stayed by the Supreme Court.
👀 கவனிக்க வேண்டியவை
Investors should balance the steady dividend payout against the slight decline in annual revenue and profit. Close monitoring of the Supreme Court's final verdict on the CCI penalty is advised as it could impact future cash flows.
UBL Q1 2026 Update: Premium Segment Grows Mid-Teens; Total Volume Up Mid-Single Digit
Heineken N.V., the promoter group of United Breweries, reported that India operations saw low-single-digit net revenue growth for the January-March 2026 quarter. Total volumes grew by a mid-single-digit percentage, which includes contract brewing volumes now classified as licensed volume. The premium segment was a key driver, delivering strong mid-teens growth led by the Kingfisher Ultra brand. To further strengthen its mainstream market leadership, the company also launched Kingfisher Smooth.
முக்கிய அம்சங்கள்
Net revenue for India operations grew by a low-single-digit percentage in Q1 2026Total volume increased by a mid-single-digit percentage including licensed volumesPremium segment delivered strong performance with mid-teens growth led by Kingfisher UltraLaunched Kingfisher Smooth, a lower bitterness beer, to reinforce mainstream segment leadership
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong premiumization trend which typically supports higher margins. Monitor the upcoming full earnings release for specific EBITDA impact and the market reception of the new Kingfisher Smooth launch.
United Breweries Chief Sales Officer Rakesh Kumar Resigns Effective April 30, 2026
United Breweries Limited (UBL) has announced the resignation of Mr. Rakesh Kumar, who served as the Chief Sales Officer and Director - Sales. The resignation is set to be effective from the close of business hours on April 30, 2026. Mr. Kumar is departing the company to pursue professional opportunities outside the organization. This transition marks a change in the senior leadership team responsible for the company's primary revenue-generating function.
முக்கிய அம்சங்கள்
Mr. Rakesh Kumar has resigned from his position as Chief Sales Officer and Director - Sales.The effective date for the cessation of his role is April 30, 2026.The resignation is attributed to the executive's decision to pursue external opportunities.The company has formally acknowledged the resignation under Regulation 30 of SEBI LODR.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the appointment of a successor to ensure there is no disruption in the company's sales execution and market share strategies. While management exits are common, the Sales head is a critical role for a consumer-facing company like UBL.
JUBLCPL Receives NSE and BSE No-Objection for Demerger into Jubilant Agri Solutions
Jubilant Agri and Consumer Products Limited (JUBLCPL) has received the formal 'No Objection' observation letters from both NSE and BSE for its proposed Scheme of Arrangement. This scheme involves the demerger of business undertakings into a new entity, Jubilant Agri Solutions Limited (JASL). The regulatory clearance allows the company to proceed with filing the petition before the National Company Law Tribunal (NCLT). The resulting company, JASL, is slated for listing on the exchanges within 60 days of the final NCLT order.
முக்கிய அம்சங்கள்
Received No-Objection Certificates from NSE and BSE on April 17, 2026, for the demerger scheme.The observation letter remains valid for 6 months for submission to the NCLT.Jubilant Agri Solutions Limited (JASL) must commence trading within 60 days of the NCLT order receipt.Company mandated to disclose 3 years of Revenue, PAT, and EBITDA for both entities in the shareholder notice.The scheme remains subject to approval from shareholders, creditors, and the NCLT.
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming NCLT filing and shareholder meeting dates to understand the final valuation and business split. This demerger is a key step toward value unlocking for shareholders through the separate listing of the Agri Solutions business.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
